Why compare DBS and venous s

IgE? Allergy blood testing traditionally uses venous serum, but modern workflows also measure allergen‑specific IgE (sIgE) from dried blood spot (DBS) finger‑prick samples. This page summarizes what has been validated, where DBS works well, when a standard lab draw is preferable, and how Wyndly supports both options.

What each method means

• Dried blood spot (DBS): capillary whole blood from a finger‑prick is applied to filter paper, dried, and eluted at the lab for analysis (single‑allergen assays, panels, or microarrays).

• Venous serum/plasma: conventional phlebotomy with centrifugation and refrigerated shipment; broadly compatible with all in‑vitro sIgE platforms.

What has been validated

• Early clinical work using finger‑prick paper blood compared with serum RAST showed “virtually identical” results for aeroallergen sIgE (positive‑sample mean ratio 1.01; 95% CI 0.58–1.75), establishing feasibility of capillary/DBS for sIgE testing.

• Molecular “allergy chip” (component‑resolved) testing from paper‑dried blood/serum spots demonstrated excellent correlation to matched serum and stability of recovered IgE/IgG after storage (including up to two weeks at 37 °C), supporting DBS for multiplex allergen profiling.

• Outside of allergy, multiple large DBS antibody validations (e.g., SARS‑CoV‑2) consistently show very high serum/DBS agreement (often r ≥ 0.95) with sensitivity around the mid‑80% range and specificity ~97–100%, reinforcing that DBS immunoassays can track serum results when methods are properly validated. (These are IgG examples, not sIgE, but they support the DBS immunoassay approach.)

Assay‑platform caveat (important)

Predictive thresholds published for specific platforms (for example, ImmunoCAP kUA/L cut‑points) must not be transferred to other assay systems without validation; cross‑platform biases are well‑documented and can alter clinical decision points. If your lab uses a different sIgE platform or a modified DBS extraction, interpret results against that lab’s own validation.

Analytical notes that matter with DBS s

IgE

• Hematocrit and spot volume: classic DBS can suffer from hematocrit‑dependent spreading/volume bias; volumetric absorptive microsampling (VAMS) devices mitigate this by collecting a fixed volume.

• Elution/dilution: extracted spots are diluted before analysis; laboratories must validate limits of detection/quantitation and reference ranges for their DBS workflow rather than copy serum cut‑offs.

• Stability: allergen‑specific antibodies in paper‑dried samples remain analytically stable under a range of temperatures; the molecular‑array DBS work reported robust signals after storage up to 37 °C.

• Matrix/total IgE effects: when total IgE is very low or extremely high, expressing results as a specific‑IgE/total‑IgE index can improve interpretation—this principle applies to serum and, when validated, to DBS workflows.

When DBS is a good choice

• You need a painless, at‑home collection (pediatrics, needle‑averse patients, travel/remote settings).

• Screening or longitudinal monitoring of environmental allergen sensitization, especially when trends (up/down) matter more than a single absolute threshold.

• Component‑resolved profiling via microarray from mailed paper spots (when supported by the testing lab).

When a venous lab draw is preferable

Choose a standard venous sample if any of the following apply:

• You need results referenced to well‑established, assay‑specific decision points (for example, when prior thresholds or longitudinal data are tied to a serum platform).

• Unexpected low‑level positives require confirmation near the assay’s limit of quantitation.

• You’re ordering extensive concurrent labs (e.g., total IgE, eosinophils, other biomarkers) or anticipate repeat add‑on tests that are more practical from serum.

DBS vs venous s

IgE at a glance | Dimension | Dried blood spot (finger‑prick) | Venous serum/plasma | |---|---|---| | Collection & logistics | Home finger‑prick; ambient mail; minimal biohazards | Phlebotomy; cold‑chain/refrigerated shipping | | Published performance vs serum | Early RAST study reported “virtually identical” results; component‑resolved testing shows excellent correlation and heat stability; broader DBS immunoassays often r ≥ 0.95 with high specificity | Gold standard reference for many assay‑specific cut‑points and published PPV/NPV data | | Key analytical caveats | Hematocrit/spot‑volume effects, extraction dilution, lab‑specific cut‑offs | Fewer pre‑analytical biases; widely standardized reference intervals | | Best use cases | Remote/pediatric sampling; trend monitoring; broad screens | Decision points tied to specific platforms; complex add‑on testing | | Typical turnaround | Fast once received by lab; mailing time varies | Fast within network labs |

Practical guidance for clinicians and patients

• Don’t mix thresholds: do not apply ImmunoCAP serum cut‑points to other assays or to an unrelated DBS method. Use only the lab’s validated interpretive criteria.

• Watch the low end: treat weak positives near the limit of detection as provisional; confirm with a venous sample if the decision will change care.

• Trend‑based follow‑up: for immunotherapy monitoring or seasonal tracking, consistent sampling on the same platform (DBS‑>DBS or serum‑>serum) is preferable.

How Wyndly supports both paths

• At‑home, CLIA‑certified finger‑prick testing that measures blood IgE to identify environmental allergen sensitizations, interpreted by a Wyndly physician.

• Prefer a lab draw? Ask your Wyndly doctor to order an FDA‑cleared ImmunoCAP® blood test at Quest Diagnostics; we support in‑person phlebotomy when that’s the better fit.

Call to action

• If you want a standard venous draw, message your Wyndly care team and request a Quest Lab blood test order.

• If you’re comfortable with at‑home sampling, start with the Wyndly finger‑prick kit and review results with your doctor online.

References (selected)

• Paper‑dried blood/serum spots enable stable, multi‑allergen molecular testing with excellent correlation to serum and heat stability.

• Finger‑prick DBS vs serum for aeroallergen RAST: virtually identical results (positive‑sample mean ratio ≈1.01).

• Cross‑platform sIgE variability cautions; do not transfer decision thresholds across assays.

• DBS immunoassays in large cohorts (SARS‑CoV‑2) show strong serum agreement, supporting DBS as a robust immunoassay matrix.

• DBS analytical considerations: hematocrit/spot‑volume bias and VAMS mitigation.